Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled Study of Intermittent Doses of CERC-301 in the Treatment of Subjects With Severe Depression Despite Antidepressant Treatment

NCT02459236 is registered in ClinicalTrials.gov with Avalo Therapeutics, Inc. as lead sponsor.

NCT NCT02459236
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02459236 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled Study of Intermittent Doses of CERC-301 in the Treatment of Subjects With Severe Depression Despite Antidepressant Treatment
Lead sponsor
Avalo Therapeutics, Inc.
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2015
Completion date
December 31, 2016
Enrollment
115 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

major depressive disorder